Drug Therapy in the Progressed CML Patient with multi-TKI Failure

Area of Science:

• Hematology
• Pharmacology
• Oncology

Background:

• Chronic myeloid leukemia (CML) management requires sequential tyrosine kinase inhibitor (TKI) therapy.
• Multi-TKI failure presents a significant challenge in CML treatment.
• Limited therapeutic options exist for patients with progressive CML after sequential TKI use.

Purpose of the Study:

• To outline the pharmacotherapy for third-line management of CML.
• To review current treatment strategies for CML with multi-TKI failure.
• To provide guidance on drug selection and transplant considerations.

Main Methods:

• Literature search of PubMed focusing on clinical trials, guidelines, and expert opinions.
• Review of available TKI (bosutinib, ponatinib, dasatinib, nilotinib) and non-TKI (omacetaxine mepussecinate, IFN, PEG-IFN) therapies.
• Analysis of treatment recommendations for different CML phases and mutational status.

Main Results:

• Allogeneic stem cell transplant (alloSCT) is recommended for progressing CML with multi-TKI failure, considering donor availability and risk scores.
• Second-generation TKIs (nilotinib, dasatinib) are options for CP-CML if not previously used.
• Third-generation TKIs (bosutinib, ponatinib) are indicated for double- or triple-TKI resistant patients.
• Ponatinib or omacetaxine mepesuccinate is required for T315I mutation before alloSCT.
• AP/BC-CML with multi-TKI failure requires potent TKIs (ponatinib, dasatinib) with chemotherapy before alloSCT.

Conclusions:

• Treatment decisions for third-line CML management depend on disease phase, prior therapies, and mutational status.
• AlloSCT is a key option for advanced CML after TKI failure.
• Careful monitoring for disease response and drug toxicity is crucial.